What is Infant Bacterial Therapeutics AB Market Cap?
Infant Bacterial Therapeutics ABIFTBF 29 Market Cap is $86.23 Mil as of Jun. 29, 2026. GuruFocus rates IFTBF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,428 Biotechnology companies, Infant Bacterial Therapeutics AB ranks worse than 53.85% on this metric.
Infant Bacterial Therapeutics AB's quarterly market cap
declined
from Sep. 2025 ($110.46 Mil) to Dec. 2025 ($64.39 Mil) but then
increased
from Dec. 2025 ($64.39 Mil) to Mar. 2026 ($83.25 Mil).
Infant Bacterial Therapeutics AB's annual market cap
increased
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($110.46 Mil) but then
declined
from Dec. 2024 ($110.46 Mil) to Dec. 2025 ($64.39 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Infant Bacterial Therapeutics AB's Enterprise Value for Today is $72.70 Mil.
Infant Bacterial Therapeutics AB (OTCPK:IFTBF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Infant Bacterial Therapeutics AB Market Cap Related Terms
Infant Bacterial Therapeutics AB Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infant Bacterial Therapeutics AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Infant Bacterial Therapeutics AB's Market Cap falls into.
Infant Bacterial Therapeutics AB Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infant Bacterial Therapeutics AB (IFTBF) has a Market Cap of $86.23 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Infant Bacterial Therapeutics AB and its competitors. According to the industry distribution chart, Infant Bacterial Therapeutics AB ranks #769 out of 1428 companies in the Biotechnology industry, placing it in the top 53.9%.
Is Infant Bacterial Therapeutics AB's Market Cap too high?
Infant Bacterial Therapeutics AB's current Market Cap is $86.23 Mil. The Biotechnology industry median Market Cap is 114.03. Infant Bacterial Therapeutics AB's value of $86.23 Mil is 24.4% below this industry median. Based on the distribution chart, Infant Bacterial Therapeutics AB ranks #769 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Infant Bacterial Therapeutics AB ranks #769 out of 1428 companies for Market Cap. This places Infant Bacterial Therapeutics AB in the lower half of its industry. The industry median Market Cap is 114.03. Infant Bacterial Therapeutics AB's value of $86.23 Mil is 24.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infant Bacterial Therapeutics AB's current Market Cap of $86.23 Mil is 24.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Infant Bacterial Therapeutics AB and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infant Bacterial Therapeutics AB's current Market Cap is $86.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (IFTBF) has a current Market Cap of $86.23 Mil. The current Market Cap is $86.23 Mil and 24.4% below the Biotechnology industry median of 114.03. Infant Bacterial Therapeutics AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (IFTBF), the current Market Cap is $86.23 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Infant Bacterial Therapeutics AB Business Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
29GF Score
Get the complete analysis for IFTBF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IFTBF has been successfully added to your 
